Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
- 1 January 2009
- journal article
- research article
- Published by Informa UK Limited in Amyotrophic Lateral Sclerosis
- Vol. 10 (5-6), 378-383
- https://doi.org/10.3109/17482960902803432
Abstract
Our objective was to assess the efficacy and safety of 40 mg/day glatiramer acetate (GA) in patients with ALS. We conducted a double-blind, randomized, placebo-controlled, multicentre trial. Three hundred and sixty-six patients with definite, probable or probable laboratory supported ALS and a slow vital capacity ≥ 70% were randomly assigned to treatment with placebo or 40 mg GA daily. The primary intention-to-treat analysis was the comparison between the two treated groups of the rates of deterioration on the ALSFRSR scale. The secondary outcome measure was time to death, tracheostomy or permanent assisted ventilation. Safety and tolerability of GA were evaluated. After 52 weeks of follow-up, the slope of the ALSFRSR score was comparable in the both groups (placebo, −1.00±0.06/month; GA, −1.05±0.06/month; p=0.48). The secondary endpoint was non-significant with 159 patients (87.4%) alive in the placebo group and 162 patients (88.1%) in the GA group (log rank, p=0.75). The most common events were the injection site reactions (76.1% in the GA group, 14.8% in the placebo group), comparable to the known profile of 20 mg GA. In conclusion, GA at a dose of 40 mg/day did not show any beneficial effect in ALS patients, and safety and tolerability of GA were good in this population.Keywords
This publication has 27 references indexed in Scilit:
- T cells in amyotrophic lateral sclerosisEuropean Journal of Neurology, 2008
- Neurogenesis and Neuroprotection in the CNS — Fundamental Elements in the Effect of Glatiramer Acetate on Treatment of Autoimmune Neurological DisordersMolecular Neurobiology, 2007
- ALS: A Disease of Motor Neurons and Their Nonneuronal NeighborsNeuron, 2006
- The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALSMolecular and Cellular Neuroscience, 2006
- Glatiramer acetate in multiple sclerosis: update on potential mechanisms of actionThe Lancet Neurology, 2005
- Controlled Autoimmunity in CNS Maintenance and Repair: Naturally Occurring CD4+CD25+ Regulatory T-Cells at the Crossroads of Health and DiseaseNeuroMolecular Medicine, 2005
- UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALSAnnual Review of Neuroscience, 2004
- Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivoBrain, 2004
- Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic InterventionJournal of Pharmacology and Experimental Therapeutics, 2003
- Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosisJournal of Neuroimmunology, 2001